PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2451317

Stromal composition in bronchogenic carcinomas--morphometric structure analysis.

A Fisseler-Eckhoff·E Snyder·R Achatzy·W P Kunze·K M Müller
View original source ↗Export metadata ↓

Abstract

So far little is known about the pathogenesis and development of the stroma in bronchogenic neoplasia. Clinical and radiological findings and morphological pictures of the tumor taken just after resection, don't reveal information about the pathogenesis and duration of the development of the scar tissue. Using an automatic image analyser (Quantimet 720, Imanco) it was possible to do morphometrical studies of bronchial carcinomas. We correlated the quantity of the stromal reaction in bronchial carcinomas to the size and histological type of the tumor. 60 peripheral, completely excised bronchial tumors were studied using post mortem and surgically removed specimens (25 adenocarcinomas, 22 squamous cell carcinomas, 13 oat cell carcinomas). The mesenchyme was studied histologically and morphometrically at the point of largest circumference of the tumor. Different histological stains were used to identify and correlate epithelial, mesenchymal and necrotic parts of the tumor. Adenocarcinomas on average have 48% stromal composition and even tumors sized 1.5-3 cm2 show evidence of extensive scar tissue. Squamous cell carcinomas have 37% and oat cell carcinomas have 30% fibrous tissue composition. Large adenocarcinomas have less stroma whereas large squamous cell carcinomas showed a relative increase in stromal composition. None of the above was shown in oat cell carcinomas. The amount of stromal tissue therefore depends on the histological tumor type.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

AdenocarcinomaCarcinoma, BronchogenicCarcinoma, Small CellCarcinoma, Squamous CellHumansLung NeoplasmsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Fisseler-Eckhoff, E Snyder, R Achatzy, W P Kunze, K M Müller. 1987. Stromal composition in bronchogenic carcinomas--morphometric structure analysis.. https://doi.org/10.1055/s-2007-1020281

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization.

Resveratrol (3,5,4'-trihydroxystilbene) a natural polyphenol present in medicinal plants, grapes and wines, has potent chemopreventive properties on intestinal carcinogenesis. A methylated derivative (Z-3,5,4'-trimethoxystilbene: R3) was synthesized. R3 at 0.3 microM exerted a 80% growth inhibition of human colon cancer Caco-2 cells and arrested growth completely at 0.4 microM (R3 was 100-fold more active than resveratrol). The cis conformation of R3 was also 100-fold more potent than the trans isomer. R3 (0.3 microM) caused cell cycle arrest at the G2/M phase transition. The drug inhibited tubulin polymerization in a dose-dependent manner (IC50=4 microM), and it reduced also by 2-fold ornithine decarboxylase and s-adenosylmethionine decarboxylase activities. This caused the depletion of the polyamines, putrescine and spermidine, which are growth factors for cancer cells. R3 inhibited partially colchicine binding to its binding site on tubulin, indicating that R3 either partially overlaps with colchicine binding or that R3 binds to a specific site of tubulin that is not identical with the colchicine binding site modifying colchicine binding by allosteric influences. The resveratrol derivative (Z)-3,5,4'-trimethoxystilbene (R3) is an interesting anti-mitotic drug that exerts cytotoxic effects by depleting the intracellular pool of polyamines and by altering microtubule polymerization. Such a drug may be useful for the treatment of neoplastic diseases.

Adenocarcinoma↗
PubMed2003

Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.

Expression of Fas ligand (FasL/CD95L) may help to maintain colon cancers in a state of immune privilege by inducing apoptosis of antitumor immune effector cells. Colon tumor-derived cell lines appear to be relatively insensitive to apoptosis mediated by their own or exogenous FasL in vitro, despite expression of cell surface Fas. In our present study, we sought to investigate if FasL upregulated in human colon cancers leads to any increase in apoptosis of the tumor cells in vivo. FasL and Fas receptor (APO-1/CD95) expression by tumor cells were detected immunohistochemically. Apoptotic tumor cell death was detected by immunohistochemistry for caspase-cleaved cytokeratin-18. FasL expression did not correlate with the extent of apoptosis of tumor cells. There was no significant local difference in the frequency of apoptosis of tumor cells between tumor nests that expressed FasL (mean = 2.4%) relative to those that did not (mean = 2.6%) (p = 0.625, n = 10; Wilcoxon signed rank). FasL expressed by the tumor cells appeared to be functional, since FasL expression in tumor nests correlated with diminished infiltration of tumor-infiltrating lymphocytes (TILs). TILs were detected using immunohistochemistry for CD45. Expression of FasL by tumor nests was associated with a mean 4-fold fewer TILs relative to FasL-negative nests (range 2.4-33-fold, n = 10, p < 0.003). Together, our results indicate that colon tumors are insensitive to FasL-mediated apoptosis in vivo.

Adenocarcinoma↗
PubMed2003

Influence of TNFA on the formation of liver metastases in a syngenic mouse model.

The level of TNFalpha expression is increased after partial hepatectomy, and experimental evidence exists that TNFalpha plays a key role in liver regeneration. Contradictory results are reported about the influence of TNFalpha on tumor growth: on the one hand, stimulation of tumor growth in various animal models and, on the other hand, intraperitoneally administered TNFalpha leads to reduced metastasis formation. TNFalpha may be one responsible factor for increased metastasis formation after surgical trauma. The objective of our study was to clarify the influence of TNFalpha on the formation of liver metastases in a syngenic mouse model in vivo. We used a novel marker system, EGFP transfected C26 tumor cells for in vivo observation of metastasis formation by intravital microscopy. We analyzed the effect of intraperitoneal TNFalpha-injection on tumor cell adhesion, extravasation and tumor development. The expression of ICAM-1, VCAM-1 and E-Selectin was measured by Western blot and immunohistochemical staining. Tumor load was assessed by determining EGFP in Western blots. GdCl(3) was employed 24 and 48 hr before tumor cell injection to selectively deplete the liver of functioning Kupffer cells. We observed significantly more extravasated tumor cells in the TNFalpha-pre-treated animals at early time points with increased expression of adhesion molecules. Measurement of the EGFP levels showed fewer liver metastases in the TNFalpha-pretreated animals at day 8. After GdCl(3) pretreatment even lower levels of EGFP, i.e., fewer metastases and also lower expression levels of ICAM-1, VCAM-1 and E-Selectin could be observed. TNFalpha, acts in a bidirectional manner: whereas TNFalpha facilitates tumor cell adhesion and extravasation of C26 tumor cells by inducing the expression of adhesion molecules, at later time points, TNFalpha seems to hinder the formation of liver metastases.

Adenocarcinoma↗